New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now ...

The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the market – but J&J thinks the broad label for Imaavy (nipocalimab) will ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder.